Starling Oncology, Inc. (STLN) Market Cap & Valuation Ratios
Starling Oncology, Inc. (STLN) has a market cap of $683.9M and a price-to-sales ratio of 1.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
STLNStarling Oncology, Inc.Follow STLN — free
—
Price chart with a free account
- Market cap
- 683.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
medical care facilities · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| STLN | 0.7 | — | 1.2 | — | -0.5% | +38% | -4% | -105% |
| SNDA | 1.6 | — | 6.0 | 126.6 | -4.2% | +49% | -13% | -4% |
| AGL | 1.5 | — | 0.2 | — | -5.6% | +0.3% | -5% | -146% |
| PNTG | 1.5 | 46.0 | 1.5 | 22.7 | 2.4% | +38% | 6% | 8% |
| NUTX | 1.4 | 8.2 | 1.5 | 3.3 | 19.1% | +7% | 43% | 139% |
| USPH | 1.3 | — | 1.9 | 15.3 | 4.8% | +11% | 9% | 9% |
| INNV | 1.3 | — | 1.2 | 50.9 | 3.9% | +16% | 0.3% | 1.0% |
| SBC | 0.5 | 11.2 | 2.3 | 5.8 | 11.2% | -7% | 37% | 40% |
| MCTA | 0.5 | — | 103.8 | 2672.0 | -0.3% | -23% | -0.6% | -4% |
| SRTA | 0.4 | — | 1.5 | — | -12.0% | +67% | -8% | -10% |
| CYH | 0.4 | 1.6 | 0.8 | 5.5 | — | -5% | 11% | 14% |
| Median of these 10 | 9.7 | 1.5 | 19.0 | 2.4% | +9% | 3% | 5% |
; EV/Sales 1.2 vs. 1.5.
Growth vs. price
each dot a company · hover or tap for valuesSTLN and SNDA and AGL and USPH and INNV and MCTA and SRTA have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Starling Oncology, Inc. — questions
- What is Starling Oncology, Inc.'s market cap?
- $683.9M.
- What is Starling Oncology, Inc.'s price-to-sales ratio?
- 1.2.
Every figure on this page comes from Starling Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.